NGS - Genetron: 3 Reasons To Stay Bullish On China's Early-Stage Cancer Screening

• China has a considerably large gene pool, a decisive success factor in conducting prospective research in early-stage cancer studies. Local bureaucracy has the power to lead nationwide research.
• As the early cancer-screening technology matures, the commercial strategy at the current stage is more critical. In China's blue-ocean market, Genetron has the first-mover advantage in market deployment.
• GTH recently engaged in a national key cohort study at a scale of 10 thousand patients for prospective cancer research.
• Compared to pan-cancer detection developer Burning Rock, Genetron focuses on specific types and moves faster on business expansion.

For further details see: